A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT3
A phase 1/2 trial of PM8002, Bevacizumab in colorectal cancer, run by BioNTech SE, now recruiting.
Overview
A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer is a phase 1/2 interventional study registered as NCT07079631 by BioNTech SE, with 482 participants planned, started 2025-07-18 and due to reach its primary completion in 2030-12. Interventions recorded: BNT314, Pumitamig, SoC chemotherapy treatment 1, SoC chemotherapy treatment 2, Bevacizumab. Conditions listed: Metastatic Colorectal Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialPM8002 (BNT327) in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
Shares PM8002, BioNTech, Colorectal cancer.
- TrialPM8002 in the Treatment of Patients With Advanced Solid Tumors
- TrialA Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
- TrialA First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors
- TrialA Study of PM8002 in Combination With Chemotherapy in Patients With SCLC
- TrialA Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC
- TrialPM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC
- TrialA Study of PM8002 in Combination With Chemotherapy in Patients With NEN